Mesna Dosing for Cyclophosphamide Overdose
For cyclophosphamide poisoning/overdose, administer mesna plus aggressive saline diuresis as the primary uroprotective strategy, though specific dosing protocols for acute overdose are not established in the literature.
Critical Context: Limited Evidence for Overdose Scenarios
The available evidence addresses therapeutic cyclophosphamide dosing, not acute poisoning. However, the principles can be extrapolated with important caveats:
Guideline-Based Recommendations for High-Dose Cyclophosphamide
Mesna plus saline diuresis or forced saline diuresis is recommended to decrease urothelial toxicity associated with high-dose cyclophosphamide 1. This ASCO guideline specifically addresses the stem-cell transplantation setting where cyclophosphamide doses are highest.
Extrapolating to Overdose Situations
In an overdose scenario, apply the high-dose cyclophosphamide principles with modifications:
Mesna Dosing Strategy:
- Continuous infusion approach is preferred over bolus dosing in overdose situations
- Based on high-dose protocols: Start with mesna at 100% of the cyclophosphamide dose administered as continuous infusion 2
- Continue mesna infusion for 24 hours after cyclophosphamide clearance is expected (longer than standard protocols given potential delayed metabolism)
Rationale: Research demonstrates that continuous mesna infusion maintains constant urinary free thiol concentrations, providing superior bladder protection compared to intermittent bolus dosing where protection gaps occur 3. In overdose, these gaps could be catastrophic.
Practical Dosing Algorithm
- Immediate initiation: Begin mesna infusion as soon as cyclophosphamide overdose is recognized
- Dose calculation: If cyclophosphamide dose is known, use 100% weight-equivalent mesna dose
- If dose unknown: Consider empiric mesna 10-20 g/day by continuous infusion (based on presumed high exposure)
- Duration: Continue for minimum 48-72 hours or until no cyclophosphamide metabolites detectable in urine
- Concurrent aggressive hydration: Force diuresis with IV fluids targeting urine output >150-200 mL/hour
Critical Caveats
The FDA label notes that mesna overdose (4.5-6.9 g) caused hypersensitivity reactions including hypotension, shortness of breath, asthma exacerbation, rash, and flushing 4. Monitor closely for these reactions when using high mesna doses.
Mesna does NOT protect against systemic cyclophosphamide toxicity - it only provides uroprotection. Research clearly demonstrates mesna can partially reduce bone marrow toxicity and systemic effects, but this is NOT its primary purpose 5. The overdose patient requires:
- Hematologic monitoring for severe myelosuppression
- Infection prophylaxis/treatment
- Cardiac monitoring (cyclophosphamide cardiotoxicity)
- Management of other systemic toxicities
Evidence Quality Limitations
No high-quality evidence exists specifically for cyclophosphamide poisoning management. The recommendations are extrapolated from:
- High-dose chemotherapy protocols (strongest available evidence) 1, 2
- Pharmacokinetic studies showing mesna metabolism patterns 3
- General toxicology principles
The comparison study showing mesna at 100% cyclophosphamide dose was equally effective as continuous bladder irrigation for preventing severe hemorrhagic cystitis provides the best evidence for dosing adequacy 2.
Monitoring Requirements
- Urinalysis every 4-6 hours for hematuria
- Complete blood counts daily (nadir expected weeks 1-2)
- Renal function monitoring
- Cardiac monitoring if high-dose exposure suspected
- Urine output - maintain >100 mL/hour minimum
Bottom line: Use continuous mesna infusion at 100% of cyclophosphamide dose (or empiric high-dose if amount unknown) combined with aggressive hydration, recognizing this addresses only bladder toxicity while comprehensive supportive care manages systemic toxicity.